J Biol Chem, Vol. 274, Issue 32, 22775-22784, August 6, 1999
Independent SH2-binding Sites Mediate Interaction of Dok-related
Protein with RasGTPase-activating Protein and Nck*
Peter
Lock
,
Franca
Casagranda, and
Ashley R.
Dunn
From the Ludwig Institute for Cancer Research and the Cooperative
Research Center for Cellular Growth Factors, P. O. Box 2008, Royal
Melbourne Hospital, Parkville 3050, Australia
 |
ABSTRACT |
A murine embryonic cDNA library was screened
for potential substrates of the Src family kinase, Lyn, using a
phosphorylation-screening strategy. One cDNA that we identified
encodes Dok-related protein (DokR), a protein with homology to
p62dok (Dok), and members of the insulin receptor substrate-1
family of proteins. Analysis of murine tissue extracts with
DokR-specific antisera revealed that DokR protein is expressed at
highest levels in lymphoid tissues. Co-expression of a FLAG
epitope-tagged form of DokR (FLAG-DokR) with Lyn in embryonic kidney
293T cells resulted in constitutive phosphorylation of FLAG-DokR on
tyrosine residues and consequential physical association with
RasGTPase-activating protein (GAP) and the Nck adaptor protein.
Stimulation of BaF/3 hematopoietic cells co-expressing the epidermal
growth factor (EGF) receptor tyrosine kinase and FLAG-DokR with EGF
also induced phosphorylation of FLAG-DokR and promoted its association
with GAP. Immunoprecipitation experiments using DokR-specific
antibodies revealed an interaction between endogenous DokR and a
150-kDa protein that is tyrosine-phosphorylated in EGF-stimulated BaF/3 cells. The molecular basis of the interactions involving DokR with GAP
and Nck was investigated using a novel glutathione
S-transferase fusion protein binding assay and/or
site-directed mutagenesis. Tandem SH2-binding sites containing
Tyr-276 and Tyr-304 were shown to mediate binding of DokR to GAP,
whereas Tyr-351 mediated the binding of DokR to Nck. These results
suggest that DokR participates in numerous signaling pathways.
 |
INTRODUCTION |
On the basis of their capacity for oncogenic transformation, Src
family kinases have long been suspected to regulate cell growth and
differentiation (1). In mammals, eight Src family kinases have been
identified as follows: Src, Yes, Fgr, Fyn, Lyn, Hck, Lck, and Blk. Src
family kinases have a conserved topology, consisting of a myristoylated
amino terminus, a variable region, Src homology 3 (SH3)1 and SH2 domains, a
linker region, a catalytic domain, and a regulatory tail (1-3). In
unstimulated cells, catalytic activity is repressed by two
intramolecular interactions, one involving the SH3 domain and a
proline-containing motif in the linker region, and another involving
the SH2 domain and a phosphorylated tyrosine in the tail region
(Tyr-527 in chicken Src) (1, 3). Dephosphorylation or mutation of this
tyrosine, or engagement of the SH3 or SH2 domains with specific
ligands, results in enzymatic activation.
Src family kinases are associated with cell membranes via a
myristoylated amino terminus and are physically or functionally coupled in different cell types to diverse cell surface molecules, including integrins, G-protein-coupled receptors, growth factor receptors, and antigen and antibody receptors (1). Numerous candidate
substrates have been identified that are phosphorylated on tyrosine
residues by Src family tyrosine kinases, including non-receptor
tyrosine kinases (4-6), structural proteins implicated in cytoskeletal
regulation (7-9), docking proteins (10-17), and cell surface
receptors (18-21). Genetic evidence from analysis of mice lacking one
or more Src family kinase indicates that members of this family have
both redundant and non-redundant functions (2). This is thought to be
due to the overlapping substrate specificities of different Src family
kinases, such that different members of this family phosphorylate
common targets in some tissues. Conversely, substrates that are unique
to individual Src family kinases are also likely to exist.
The Lyn tyrosine kinase is expressed in several hematopoietic lineages
including B lymphoid, myeloid, and erythroid cells and is implicated in
signal transduction pathways that control cell proliferation (22-24),
apoptosis (25, 26), differentiation (27), adhesion, and migration (28,
29). To identify potential components of Lyn-mediated signaling
pathways, we have employed a cloning strategy to detect proteins by
their capacity to act as substrates for Lyn kinase (30). We have
identified both novel and known targets of Lyn or other Src family
kinases. One potential Lyn substrate that we have detected, Dok-related
protein (DokR) (31-33), contains an amino terminus that shares
extensive similarity with the insulin receptor substrate-1 (IRS-1)
family of proteins and, like the IRS proteins, contains multiple
potential SH2-binding sites. Our results indicate that tyrosine
phosphorylation of DokR by Lyn generates specific binding sites for
RasGTPase-activating protein (GAP) and the Nck adaptor protein. We have
determined the location of the critical sites underlying these interactions.
 |
EXPERIMENTAL PROCEDURES |
Cloning of cDNAs Encoding Lyn Substrates--
Approximately
7 × 105 independent clones from a
EXlox cDNA
expression library generated from day 16 murine embryonic mRNA (Novagen) were screened for Lyn substrates essentially as described (30). Briefly, cDNA clones were immobilized on nitrocellulose filters (Micron Separations Incorporated) and the filters incubated in
kinase buffer (10 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 10 mM MgCl2, 2 mM
MnCl2, 0.1% Triton X-100, 250 µM ATP) with
1:20 diluted extracts of Sf9 cells infected with a baculovirus
encoding murine p56lyn (Lyn) (34). The tyrosine-phosphorylated
cDNA products were detected by immunoblotting (see below) with the
4G10 phosphotyrosine antibody (anti-Tyr(P)) (Upstate Biotechnology).
Positive clones were plaque-purified, their cDNA inserts rescued by
auto-subcloning in pEXlox (Novagen) according to the suppliers
protocol, and the nucleotide sequence of their 5'- and 3'-ends
determined using the chain termination method and an automated DNA
sequencer (Applied Biosystems). Sequences were scrutinized by reference
to the non-redundant nucleic acid and protein data bases using the
BLAST 2.0 program (35). Both strands of a 1615-base pair cDNA were
sequenced and found to specify a novel protein that was designated
Dok-related protein (DokR).
Constructs--
A FLAG-tagged DokR cDNA was generated by
insertion of an EcoRI-SacI-digested PCR fragment
encoding an initiator methionine, the FLAG octapeptide (DYKDDDDK), and
residues 2-44 of DokR, into a pEXlox plasmid (Novagen) containing the
sequences encoding residues 45-412 of wild type DokR. Full-length
FLAG-DokR cDNA was excised with EcoRI and
HindIII, filled with Klenow enzyme, and subcloned using
BstXI adaptors into the BstXI sites of the
mammalian expression vector pEF-BOS. Site-directed mutagenesis of
FLAG-DokR cDNA was performed by overlap-extension PCR. Mutated
cDNA fragments were dA-tailed in the presence of Taq
polymerase for 10 min at 72 °C and subcloned into pGEM-T (Promega).
Inserts were excised with NcoI and PstI, filled
with Klenow enzyme, ligated to BstXI adaptors, and inserted
into pEF-BOS. The expression plasmids, pcDNA Lyn and pcDNA
Lyn508F, encoding wild type and activated forms of murine p56lyn, were kindly provided by M. Hibbs. pEF-BOS Hck and
pEF-BOS Hck499F, encoding wild type and activated murine
p59hck, were gifts of G. Scholz. The pGS5
Src527F plasmid, which encodes activated chicken Src, was a gift of G. Superti-Furga. Constructs encoding glutathione S-transferase
(GST) fused to full-length or truncated forms of DokR were generated by
PCR. Products were directionally cloned into pGEX-4T-1 (Amersham
Pharmacia Biotech)using BamHI and EcoRI sites in
the PCR primers. pGEX constructs encoding GST alone and GST fused to
the SH3, SH2N, or SH2C domains or the SH2-SH3-SH2 region (SH2, 3, 2) of
GAP were generously provided by S. Roche, G. Scholz, and K. Harder.
GST-GAP-SH2*,3,2 and SH2,3,2* mutants in which the SH2N and SH2C
domains were inactivated by R206A and R377A amino acid substitutions,
respectively (36), were generated using overlap-extension PCR and
subcloned into the BamHI and EcoRI sites of
pGEX-4T-1. A 1:8 ratio of Pfu (Stratagene) and
Taq (prepared at LICR) DNA polymerases was used for PCR
reactions, and the nucleotide sequence of PCR products was determined.
Cell Culture, DNA Transfection, and Baculovirus
Infection--
Human 293T embryonic kidney cells were maintained in
RPMI medium containing 10% fetal calf serum (FCS) and antibiotics at 37 °C in 5% CO2. BaF3/EGFR parental cells (37) were a
gift from J. Gonez and F. Walker and were grown in RPMI with 10% FCS,
10% WEHI-3B conditioned medium (as a source of IL-3), and antibiotics at 37 °C in 5% CO2. Sf9 insect cells were grown
at 27 °C in Grace's medium containing 10% FCS. Transient
transfection of 293T cells with pEF-BOS or pcDNA-based expression
vectors was performed using polyethyleneimine-mediated DNA transfer
(38). Approximately 2 × 106 cells were seeded into
10-cm dishes approximately 24 h prior to transfection. Solutions
containing the plasmid DNA(s) (15 µg total per 10-cm dish) and 2 mM polyethyleneimine, pH 7, both in 0.15 M
NaCl, were vortexed and incubated at room temperature for 10 min.
DNA/polyethyleneimine mixture was added to the pre-washed cells, which
were in 8.0 ml of serum-free medium. Cells were incubated for 4 h,
and the medium was gently removed and replaced with RPMI containing
10% FCS. Cells were assayed after 60-72 h. BaF/3 cell lines
expressing the EGF receptor and FLAG-DokR were generated by
electroporation of 4 × 106 BaF3/EGFR cells (37) with
pEF-BOS/FLAG-DokR (18 µg) and pGK-Puro (2 µg) at 270 V and 960 microfarads. Stable transfectants were selected in 2 µg/ml puromycin
(Sigma). For EGF stimulation experiments, BaF3/EGFR/FLAG-DokR cells
were serum-starved for 6 h and stimulated for various times with
100 ng/ml murine EGF (prepared by T. Domagala and E. Nice). Sf9
insect cells were infected with a baculovirus encoding p56lyn
(a gift of M. Hibbs) (34) and harvested after 72 h.
Antibodies--
Anti-DokR.1 and anti-DokR.2 polyclonal antisera
were generated by immunizing rabbits with the purified GST fusion
proteins containing amino acids 260-341 and 136-309 of murine DokR
(33) (GenBankTM accession number AF059583), respectively.
Rabbit polyclonal anti-DokR.3 antibodies were raised against a
diphtheria toxin-conjugated peptide (Auspep) corresponding to the
carboxyl-terminal DokR residues 397-412. Monoclonal FLAG M2 antibody
and antibody-agarose conjugate were obtained from Integrated Sciences
or Sigma. Phosphotyrosine antibody (4G10) was obtained from Upstate
Biotechnology. Rabbit polyclonal antibodies against GAP and GST were
gifts of S. Roche. Anti-Crk was purchased from Transduction
Laboratories, and anti-CrkL and anti-Lyn sera were from Santa Cruz
Biotechnology, respectively. Polyclonal anti-human Nck antibodies
(Upstate Biotechnology) were a generous gift of R. Wettenhall and W. Yu.
Preparation of Tissue and Cell Extracts, Immunoprecipitation, and
Immunoblot Analysis--
Transfected 293T cells or Sf9 cells
infected with p56lyn baculovirus were washed in ice-cold TBS
containing 100 µM NaVO4 and 2 mM
DTT. BaF3/EGFR/FLAG-DokR cells were harvested by centrifugation and
lysed without washing. Cultured cells were lysed in 1.0 ml of cold
Lysis buffer (20 mM HEPES, pH 7, 150 mM NaCl,
1% Nonidet P-40 containing 100 µM NaVO4, 10 mM NaF, 2 mM DTT, and protease inhibitors).
Mouse tissues were dissected from an 8-week-old 129OLA × C57Bl/6
mixed background male. Thymus was also prepared from a 4-week-old male
of the same genetic background. Tissues were homogenized for 10-30 s
in 2 volumes of ice-cold RIPA buffer (20 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.1% SDS, 1% sodium deoxycholate, 1%
Triton X-100) containing 2 mM DTT and protease inhibitors
using an automated homogenizer (Polytron). Clarified extracts
containing 2 mg of protein (mouse tissues), 200-400 µg of protein
(293T and Sf9 cells), or prepared from equivalent cell numbers
(1-5 × 107 cells; BaF/3 cells) were incubated with
1-2 µl of crude antiserum or 2 µg of purified IgG plus 10 µl of
protein A-Sepharose for 1 h at 4 °C. For anti-FLAG
immunoprecipitations, lysates were incubated with 10 µl of FLAG M2
affinity beads. Immune complexes were washed 4 times with RIPA buffer
containing 100 µM NaVO4 and 2 mM
DTT. In some experiments, FLAG immunoprecipitates were incubated with
100 µM FLAG M2 peptide (Sigma) to elute FLAG-tagged
proteins. Samples were boiled in SDS sample buffer, resolved by 10%
SDS-PAGE, and transferred to nitrocellulose filters (Micron Separations Inc.) using a semi-dry electroblot apparatus (Hoefer) according to the
manufacturers' specifications. Immunoblot analysis was performed using
the following primary antibodies: anti-Tyr(P), anti-GAP, anti-FLAG,
anti-Crk, anti-CrkL, anti-DokR.1, anti-DokR.3 or anti-Nck (see under
"Antibodies"). Immunoreactive proteins were detected using
horseradish peroxidase conjugates of protein A, anti-mouse IgG, or
anti-rabbit IgG (Bio-Rad) in conjunction with enhanced
chemiluminescence (ECL) (Amersham Pharmacia Biotech) and exposure to
x-ray film (Fuji).
GST Fusion Protein Binding Assays--
BL21(DE3) cells
transformed with pGEX plasmids encoding GST fusion proteins were
treated with 1-100 µM
isopropyl-1-thio-
-D-galactopyranoside for 1-3 h at
37 °C. GST fusion proteins were extracted and purified on
glutathione-Sepharose (Amersham Pharmacia Biotech) according to the
manufacturer's instructions. Tyrosine-phosphorylated GST-DokR fusion
proteins were prepared as follows: purified fusion proteins (1 µg)
were incubated with a Lyn immunoprecipitate (prepared from Sf9
cells overexpressing Lyn, see above) in kinase buffer containing 250 µM ATP and 100 µM NaVO4 at
30 °C for 30 min. Lyn kinase-treated or non-treated GST-fusion
proteins (200 ng) were adsorbed to 10 µl of glutathione-Sepharose for
30 min, washed once with PBS, and then incubated for 1 h with
lysates prepared from transfected or untransfected 293T cells (400 µg). Complexes were washed with RIPA buffer and analyzed by SDS-PAGE
and immunoblotting as described above.
 |
RESULTS |
Identification of Lyn Substrates--
Recently, we reported (30) a
strategy for identifying potential substrates of tyrosine kinases.
Here, this method was applied to isolate substrates of the Src family
kinase, Lyn. Briefly, nitrocellulose filters containing a murine
embryonic cDNA expression library were incubated with Lyn kinase in
the presence of ATP and then probed with a phosphotyrosine antibody.
Approximately 7 × 105 independent cDNA clones
were screened, of which 30 encoded products that reacted strongly with
the phosphotyrosine antibody (not shown). Clones were plaque-purified
and shown by nucleotide sequencing to represent cDNAs encoding 9 different proteins.
Four of the proteins identified had been shown previously to be
substrates of Lyn or other Src family kinases as follows: cortactin/EMS1 (7), hematopoietic lineage cell-specific protein 1/Lck-binding protein 1 (HS1/LckBP1) (13, 14), Crk-associated substrate
(p130cas) (10), and embryonic Fyn substrate/Src-interacting
protein (11, 12). We also identified insulin receptor substrate-2 (IRS-2) (39), a protein that is phosphorylated on tyrosine residues in
response to stimulation of cells with insulin, insulin-like growth
factor-1, and several cytokines (40). In addition, we identified SH3P7,
a molecule that was initially cloned on the basis of its ability to
bind to polyproline-containing peptides (41). Although not known to be
tyrosine-phosphorylated in cells, SH3P7 nevertheless represents a
strong candidate substrate of Src family kinases since it contains
several consensus recognition sites for phosphorylation by v-Src (not
shown) and is structurally related to cortactin/EMS1 and HS1/LckBP
within its carboxyl-terminal SH3 domain (41) (not shown). One protein
that was identified shared extensive sequence similarity with
p62dok (Dok), a potential target of several receptor and
cytoplasmic tyrosine kinases and a protein that has been shown to
interact with RasGTPase-activating protein (GAP) (16, 17, 42, 43) and
Nck (43). We designated this protein Dok-related protein (DokR). Before
completing our studies on DokR, three other groups reported the
identification of this protein and named it p56dok-2 (31),
interleukin-4 receptor-
chain interacting protein (FRIP) (32), and
Dok-related protein (Dok-R) (33). In this report we will refer to the
protein as DokR.
In agreement with published reports, nucleotide sequence analysis of
the 1,615-base pair DokR cDNA indicated that it encoded a protein
of 412 residues (not shown) including 13 possible tyrosine phosphorylation sites (31-33). Data base searches revealed that murine
DokR shares 36% sequence identity with human DOK (not shown). Both
proteins contain a putative pleckstrin homology (PH) domain at the
amino terminus (residues 8-118 in mDokR) followed by a phosphotyrosine
binding (PTB) domain (residues 148-254) (not shown) (32, 33). The
carboxyl-terminal region of DokR (residues 255-412) contains 30 proline residues (Pro), representing 19% of amino acids, and contains
multiple PXXP motifs that potentially interact with SH3
domain-containing proteins (not shown) (33).
Interestingly, data base searches also revealed that the amino terminus
of DokR, including the PH and PTB domains, shares significant homology
with the insulin receptor substrate (IRS) proteins, a family of
cytosolic proteins that undergo cytokine- and growth factor-inducible
tyrosine phosphorylation and interactions with specific SH2-containing
proteins (40). Notably, no other proteins with PH domains other than
IRS-1, IRS-2, and Dok were detected in these searches (not shown),
perhaps an indication of the low sequence conservation among PH
domains. A sequence alignment of the PH/PTB region of DokR, Dok, IRS-1,
and IRS-2 is presented in Fig.
1A. The similarity between
DokR and IRS proteins within the PTB domain was noted previously (33).
However, the alignment shown in Fig. 1A reveals that the
PH/PTB domain configuration has been conserved during evolution. These
data strongly suggest that Dok, DokR, and the IRS proteins are members
of two related subfamilies.

View larger version (82K):
[in this window]
[in a new window]
|
Fig. 1.
DokR is related to the IRS and FRS2/SNT-1
protein families. A, amino acid sequence alignment of
the pleckstrin homology domains (overlined) and
phosphotyrosine binding domains (underlined) of murine
(m)DokR, mDok, mIRS-1, and human (h)IRS-2. Residues that are
identical or similar in all sequences (black shading) or in
3 out of 4 sequences (gray shading) are indicated.
Numbers indicate amino acid positions. B, PTB
domain sequence alignment of mDokR, hDokR, mDok, hDok, mFRS2 (also
known as SNT-1), hFRS2, hSNT-2, an unidentified human gene product
(hORF1), a C. elegans gene product (cORF1), hIRS-1,
hIRS-2, and mIRS-3. Identical or similar residues in all sequences
(black shading) or in more than half of the sequences
(gray shading) are indicated. Note that because of the low
sequence conservation among PTB domains, the patterns of conservation
depicted in A and B are not identical.
|
|
Several proteins with homology to the DokR PTB domain, but which lack a
PH domain, were also identified. A sequence alignment showing these
proteins together with members of the IRS family is presented in Fig.
1B. Included in this group, fibroblast growth factor (FGF)
receptor substrate 2 (FRS2) (44) or suc1-associated neurotrophic factor
target-1 (SNT-1) (45) and the related molecule, SNT-2 (45), are docking
proteins that contain a myristoylated amino terminus. Both FRS2/SNT-1
and SNT-2 are rapidly phosphorylated on tyrosine residues following
stimulation of cells with FGF or nerve growth factor.
Tyrosine-phosphorylated FRS2 then interacts with the SH2 domain of
growth factor receptor-binding protein 2, linking it to activation of
the Ras pathway (44). Human FRS2/SNT-1 is identical with the product of
an expressed sequence tag (est) designated h-dok-5 that was
reported previously (31). Two predicted proteins (designated here as
cORF1 and hORF1) that are encoded by an uncharacterized
Caenorhabdiitis elegans gene (GenBankTM
accession number AAB94991) and a human gene (GenBankTM
accession number AAC24310), respectively, also possess DokR-like PTB
domains and are therefore predicted to participate in tyrosine kinase-mediated signal transduction.
Expression Pattern of DokR Protein--
We generated rabbit
polyclonal antisera against different regions of DokR as follows:
residues 260-341 (anti-DokR.1), residues 136-309 (anti-DokR.2), and
residues 397-412 (anti-DokR.3). When tested in immunoprecipitation and
Western blot analysis, the three DokR antisera, but not the
corresponding preimmune sera, each recognized a FLAG epitope-tagged
form of DokR (FLAG-DokR) when it was ectopically expressed in 293T
cells (not shown). To determine the expression pattern of DokR protein,
we prepared extracts from a range of adult mouse tissues and analyzed
them by immunoprecipitation with the anti-DokR.2 antibody followed by
immunoblotting with the anti-DokR.1 antibody. Extracts from 293T cells
expressing FLAG-DokR and from BaF/3 cells, which were found to express
endogenous DokR (not shown), were included in the analysis as positive
controls. As shown in Fig. 2, the
antibodies detected a 56-kDa protein in a subset of tissues, including
thymus, lymph node, spleen, lung, and heart. This molecular mass is
identical to that reported for DokR (31, 33) and less than that
reported for Dok (60-62 kDa) (16, 17), suggesting that the protein
detected in the immunoprecipitates is indeed DokR. The slightly greater
molecular mass of FLAG-DokR relative to DokR isolated from tissues is
attributed to the 8 additional residues that comprise the FLAG epitope
tag. A weak band of approximately 56 kDa was detected in all samples
and is due to reactivity of protein A-horseradish peroxidase (used to detect binding of anti-DokR.1) with the IgG heavy chain of the anti-DokR.2 antibody. A protein of approximately 66 kDa, the identity of which is not known, was detected in kidney. Significantly, the
tissue distribution of DokR protein that we observed correlates closely
with the mRNA expression profiles that we and others (31-33) have
observed previously (not shown).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Tissue distribution of DokR protein.
Extracts of tissues from adult mice (2 mg of protein), BaF/3 cells (1 mg of protein), and FLAG-DokR-expressing 293T cells (400 µg) were
subjected to immunoprecipitation with anti-DokR.2 antibody.
Immunoprecipitates were resolved by SDS-PAGE, transferred to
nitrocellulose, and immunoblotted with anti-DokR.1 antiserum. A
background band that co-migrated with DokR in all samples corresponds
to the IgG heavy chain of anti-DokR.2, which is recognized weakly by
the protein A-horseradish peroxidase conjugate that was used to detect
the anti-DokR.1 probe.
|
|
Phosphorylation of DokR by Src Family Kinases Induces Association
of DokR with GAP--
To test whether Src family kinases are capable
of phosphorylating DokR in vivo, FLAG-DokR was transiently
co-expressed in 293T cells with wild type Lyn or Hck or activated
mutants of Lyn, Hck, or Src containing a phenylalanine substitution of
their conserved regulatory tyrosine (Tyr-527 in Src). Cell lysates were
immunoprecipitated with a FLAG antibody and analyzed by immunoblotting
with a phosphotyrosine antibody. Fig.
3A shows that FLAG-DokR was
strongly tyrosine-phosphorylated in cells that co-expressed either wild
type or activated Src family kinases (upper panel). Perhaps
surprisingly, the level of FLAG-DokR tyrosine phosphorylation was
similar in the presence of activated or wild type Lyn and only
moderately elevated in the presence of activated Hck compared with wild
type Hck (Fig. 3A). Presumably this is due to a relative
lack of catalytic repression of wild type Lyn (and to a lesser extent
Hck) in 293T cells by endogenous regulatory kinases (e.g.
carboxyl-terminal Src kinase) (46), which are capable of
phosphorylating the regulatory tyrosine residue of Src family
kinases.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 3.
Src family kinases phosphorylate DokR and
induce it to associate with GAP but not Crk or CrkL. A,
293T cells were transfected with vector alone or plasmids encoding
FLAG-DokR alone or FLAG-DokR plus Lyn wild type, Lyn508F, Hck
WT, Hck499F, or Src527F. Cellular extracts containing
400 µg of protein were analyzed by immunoprecipitation
(IP) with a FLAG antibody (anti-FLAG) and resolved by
SDS-PAGE followed by Western blot analysis (WB) with
anti-Tyr(P) (anti-pY) (upper panel) or GAP
(center panel) antibody. Samples of crude extract
(WCL) containing 20 µg of protein were analyzed in
parallel by immunoblotting with anti-FLAG antibody (lower
panel). B, 293T cells were transfected with vectors
encoding Lyn WT, FLAG-DokR alone, or FLAG-DokR plus Lyn
WT or Lyn508F. Anti-GAP immunoprecipitates were assayed for
FLAG-DokR association by immunoblotting with anti-Tyr(P). C,
plasmids encoding FLAG-DokR alone or FLAG-DokR plus Lyn WT were
transfected in 293T cells. Whole cell lysates and anti-FLAG
immunoprecipitates were subjected to SDS-PAGE and analyzed by
immunoblotting with anti-CrkL (upper panel), anti-Crk
(center panel), and anti-GAP (lower panel)
antibodies.
|
|
Since tyrosine phosphorylation of p62dok (Dok) by a variety of
tyrosine kinases has been shown to induce Dok to associate with GAP
(16, 17, 42), we tested whether phosphorylation of DokR by Src family
kinases also promoted its association with GAP. Immunoblot analysis of
FLAG immunoprecipitates with a GAP antibody revealed that endogenous
GAP co-immunoprecipitated with FLAG-DokR in cells that co-expressed
wild type or activated forms of Lyn, Hck, or Src (Fig. 3A, center
panel). Intriguingly, the amount of GAP associated with FLAG-DokR
in cells co-expressing wild type and activated Lyn was higher than that
observed in cells co-expressing wild type and activated Hck or
activated Src. This enhanced capacity to associate with GAP was not due
to higher total levels of phosphotyrosine on FLAG-DokR (upper
panel) but, conceivably, might be due to qualitative differences
in tyrosine phosphorylation of FLAG-DokR. Indeed, immunoblot analysis
of whole cell lysates of the transfected cells using a FLAG antibody
revealed differences in the patterns of phosphorylated FLAG-DokR
isoforms that were generated in the presence of Lyn, Hck, or Src
(lower panel). At least three electrophoretically distinct
isoforms of FLAG-DokR were detected in cells expressing wild type or
activated Lyn, whereas cells that expressed wild type or activated Hck
or activated Src contained only two major isoforms. These data reveal a
potential difference in the substrate specificities of Lyn, Hck, and
Src and suggest that Lyn preferentially phosphorylates tyrosine
residues that participate in binding to GAP. To confirm the interaction
between FLAG-DokR and GAP, we performed a reciprocal
co-immunoprecipitation experiment in which GAP was immunoprecipitated
from 293T cells expressing wild type Lyn alone, FLAG-DokR alone, or
FLAG-DokR plus wild type or activated Lyn. Immunoblot analysis with a
phosphotyrosine antibody showed that FLAG-DokR co-immunoprecipitated
with GAP from cells that co-expressed wild type or activated Lyn, but
not with GAP from cells that expressed Lyn or FLAG-DokR alone (Fig.
3B). These results clearly demonstrate that GAP is capable
of interacting with DokR in vivo and suggest that DokR
phosphorylation is necessary for this interaction.
DokR contains four tyrosine (Tyr) residues that are located in peptide
motifs where a proline (Pro) is present at position +3 relative to the
tyrosine (Tyr-197, Tyr-276, Tyr-304, and Tyr-351). When phosphorylated,
YXXP motifs represent potential binding sites for the SH2
domains of several cytoplasmic proteins, including GAP, Nck, Abl, and
Crk (43, 47). To determine whether DokR interacts with Crk or Crk-like
protein (CrkL), 293T cells were transfected with plasmids encoding
FLAG-DokR alone or FLAG-DokR plus Lyn. Cell lysates were subjected to
immunoprecipitation with FLAG antibodies and immunoblotted with CrkL,
Crk, or GAP antibodies (Fig. 3C). Whereas CrkL (upper
panel) and Crk (center panel) were readily detected in
whole cell lysates of transfected cells, we failed to detect either
protein in association with tyrosine-phosphorylated or unphosphorylated
FLAG-DokR. GAP, on the other hand, co-immunoprecipitated with
tyrosine-phosphorylated FLAG-DokR as expected (lower
panel). These data indicate that the interaction between FLAG-DokR
and GAP is specific and not simply due to overexpression of
tyrosine-phosphorylated FLAG-DokR. In a recent study, DokR was shown to
associate in a phosphorylation-independent manner with endogenous Crk
when overexpressed in 293T cells (33). It was proposed that the SH3
domains of Crk might interact with PXXP motifs present in
DokR. The reason for our failure to detect Crk in FLAG-DokR
immunoprecipitates remains unclear.
Stimulation of BaF3/EGFR Cells with EGF Induces DokR to Associate
with GAP and a 150-kDa Phosphoprotein--
Previous studies showed
that p62dok (Dok) becomes rapidly tyrosine-phosphorylated and
associated with GAP as a consequence of activation of diverse receptor
tyrosine kinases, including the epidermal growth factor (EGF) receptor
(42), the Eph family receptor, EphB2/Nuk (43), or the stem cell factor
receptor (c-Kit) (16). Here, we have tested whether stimulation of the
EGF receptor induces phosphorylation of DokR and promotes its
association with GAP. BaF/3 hematopoietic cells that ectopically
expressed the EGF receptor (BaF3/EGFR cells) (37) were co-transfected
with plasmids encoding FLAG-DokR and the puromycin resistance gene. Puromycin-resistant cell lines were isolated and tested for FLAG-DokR expression by immunoblotting with FLAG antibodies (not shown). A cell
line that expressed intermediate levels of FLAG-DokR was identified
(not shown). These cells were stimulated with EGF for a range of times,
lysed, and subjected to immunoprecipitation with FLAG or EGF receptor
antibodies. Immunoprecipitates were analyzed by immunoblotting with
phosphotyrosine, FLAG, or GAP antibodies. As shown in Fig.
4, EGF stimulation induced rapid and
transient tyrosine phosphorylation of FLAG-DokR (upper
panel) in parallel with EGF receptor activation (lower
panel). Phosphorylation of FLAG-DokR was negligible in control
cells, increased to maximal levels after 1 min, and then declined to
base-line levels by 1 h. Endogenous GAP associated with FLAG-DokR
with similar kinetics to tyrosine phosphorylation of FLAG-DokR
(third panel from top), suggesting that
phosphorylation is necessary for this interaction. Immunoprecipitates
of FLAG-DokR contained no detectable tyrosine-phosphorylated EGF
receptor suggesting that DokR does not form a stable complex with the
receptor (not shown). Our data suggest that DokR can act as a direct
substrate of the EGF receptor or is phosphorylated by an endogenous
kinase that becomes activated in BaF/3 cells following EGF
stimulation.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 4.
EGF stimulates tyrosine phosphorylation of
FLAG-DokR and its association with GAP. A, BaF/3 cells
stably expressing the EGF receptor and FLAG-DokR were starved of serum
and IL-3 for 6 h ( ) or stimulated with EGF (100 ng/ml) for 1, 5, 10, 20, or 60 min. Equivalent amounts of extract from stimulated cells
were analyzed by immunoprecipitation (IP) with anti-FLAG
(upper three panels) or anti-EGF receptor (lower
panel) antibodies. Samples were resolved by SDS-PAGE and
transferred to nitrocellulose. Blots were probed with anti-Tyr(P)
(anti-pY) (upper and lower panels), anti-FLAG
(2nd panel), or anti-GAP (3rd panel) antibodies.
WB, Western blot.
|
|
Since DokR is expressed in BaF/3 cells (see Fig. 2), we also tested
whether EGF could promote association of endogenous DokR with GAP.
BaF3/EGFR cells were serum-starved for several hours and then treated
or not treated with EGF for 2 min. DokR was immunoprecipitated from
cellular extracts with anti-DokR.1, anti-DokR.2, or anti-DokR.3 antibodies and then analyzed by immunoblotting with
anti-phosphotyrosine or GAP antibodies. As shown in Fig.
5A, EGF rapidly induced
tyrosine phosphorylation of endogenous DokR (upper panel)
and promoted its association with GAP (lower panel). A
background band that co-migrated with DokR (upper panel)
corresponds to the IgG heavy chain of the DokR antisera. Interestingly,
a tyrosine-phosphorylated protein of approximately 150 kDa (p150), the
identity of which is unknown, was detected in all three anti-DokR
immunoprecipitates from the EGF-stimulated cells but not from the
unstimulated cells (Fig. 5A, center panel).
Tyrosine-phosphorylated p150 was detected in DokR immunoprecipitates at
least 7 min after stimulation with EGF (Fig. 5B, lower
panel). These results suggest that p150 and DokR form a stable
complex in the EGF-treated cells. At present we cannot distinguish
whether the DokR-p150 complex is constitutive or induced by EGF. Long
autoradiographic exposures were required to detect p150, suggesting
that the phosphotyrosine content of p150 may be relatively low or,
alternatively, that p150 associates with DokR with low stoichiometry.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Endogenous DokR is associated with a 150-kDa
tyrosine-phosphorylated protein in EGF-stimulated cells.
A, BaF3/EGFR cells were serum- and IL-3-starved for 6 h
( ) and stimulated for 2 min with 100 ng/ml EGF (+).
Immunoprecipitates prepared with anti-DokR.1, anti-DokR.2, or
anti-DokR.3 antibodies, and samples of whole cell lysate
(WCL) were resolved by SDS-PAGE. After transfer to
nitrocellulose, the blot was probed with phosphotyrosine
(upper and center panels) or GAP antibodies
(lower panel), and bands were detected using
chemiluminescence. A 10-s (upper panel) and a 2-min exposure
(center panel) of the anti-Tyr(P) (anti-pY) immunoblot are
shown (center panel). B, BaF3/EGFR cells were
serum- and IL-3-starved ( ) or stimulated for 2 or 7 min with 100 ng/ml EGF. Extracts were immunoprecipitated with anti-DokR.2 serum and
analyzed by SDS-PAGE and immunoblotting with anti-Tyr(P) followed by
chemiluminescent detection. A 10-s (upper panel) and a 3-min
exposure (lower panel) of the anti-Tyr(P) blot are shown.
WB, Western blot.
|
|
Both GAP SH2 Domains Mediate Binding to Tyrosine-phosphorylated
DokR--
GAP contains a regulatory domain that consists of two SH2
domains (SH2N and SH2C) separated by an SH3 domain. To determine the
role of these domains in binding to DokR, we generated glutathione S-transferase (GST) fusion proteins containing the SH2N,
SH2C, and SH3 domains or the entire regulatory region (abbreviated here to SH2,3,2). Bacterially expressed GST fusion proteins were immobilized on glutathione-Sepharose and incubated with whole cell lysates prepared
from 293T cells expressing FLAG-DokR or Lyn plus FLAG-DokR. Affinity
precipitates were analyzed by immunoblotting with antibodies to
phosphotyrosine, FLAG, or GST. The results presented in Fig. 6A show that GST fusion
proteins containing either the SH2N or SH2C domain or the SH2,3,2
region of GAP bound to tyrosine-phosphorylated but not unphosphorylated
FLAG-DokR (upper and center panels). By contrast,
GST alone or a GST fusion protein containing the SH3 domain failed to
bind to FLAG-DokR irrespective of its phosphorylation state. The
secondary (anti-mouse) antibody that was used to detect FLAG-DokR
cross-reacted with the GST-SH2,3,2 fusion protein, generating a
nonspecific band in these samples. The data show that both of the GAP
SH2 domains are competent to interact with DokR.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
The SH2 domains of GAP mediate its
interaction with DokR. Equivalent amounts (200 ng of protein) of
GST alone or GST fusion proteins containing the GAP SH3 domain, the
amino-terminal SH2 domain (SH2N), the carboxyl-terminal SH2
(SH2C) domain or the SH2N, SH3 and SH2C domains
(SH2,3,2) were adsorbed to glutathione-Sepharose and
incubated with extracts (400 µg) of 293T cells expressing FLAG-DokR
(left panels) or Lyn WT plus FLAG-DokR (right
panels). Affinity precipitates were then resolved in parallel with
20 µg of whole cell lysate (WCL) by SDS-PAGE. After
transfer to nitrocellulose, the filter was probed with the following
antibodies: anti-FLAG (upper panel), anti-Tyr(P) (anti-pY)
(center panel), and anti-GST (lower panel).
B, GST fusion proteins (200 ng of protein) containing the
intact GAP SH2,3,2 region or the SH2,3,2 region in which the SH2N
domain (SH2*,3,2) or SH2C domain (SH2,3,2*) was mutated were
immobilized on glutathione-Sepharose and then incubated with equivalent
amounts of extract (400 µg) from 293T cells expressing Lyn WT plus
FLAG-DokR. Precipitates were resolved in parallel with samples of whole
cell lysate (WCL) (20 µg) by SDS-PAGE. Following transfer
to nitrocellulose, the filter was probed with anti-DokR.3 (upper
panel) and anti-GST (lower panel). WB,
Western blot.
|
|
Both GAP SH2 domains, but not the SH3 domain, also mediate binding to
the Rho family GTPase, p190RhoGAP (48, 49). Interestingly,
p190RhoGAP bound to GST fusion proteins containing both GAP SH2
domains and the SH3 domain with greater efficiency than to fusion
proteins containing only the SH2N or SH2C domain, suggesting that the
SH2 domains of GAP cooperate or synergize in binding to
p190RhoGAP. To examine the individual contribution of each SH2
domain to binding DokR, we generated GST fusion proteins containing an
inactivating mutation in either the SH2N or SH2C domain (R206A or
R377A, respectively) (36). Equivalent amounts of these GST fusion
proteins and a fusion protein with wild type SH2 domains were
immobilized on glutathione-Sepharose and incubated with lysates from
293T cells that co-expressed Lyn and FLAG-DokR. The relative amounts of
FLAG-DokR protein bound by the GST fusion proteins and the levels of
GST fusion proteins that were used in the assay were assessed by
immunoblotting with DokR or GST antisera. As shown in Fig.
6B, mutation of the SH2C domain (SH2,3,2*) had no
significant effect on the ability of the SH2,3,2 region to bind
FLAG-DokR. Intriguingly, however, mutation of the SH2N domain (SH2*3,2)
abolished binding to FLAG-DokR. These results reveal a surprising
inhibitory effect of the SH2 and/or SH3 domain on the intrinsic
potential of the SH2C domain to bind to DokR (see Fig. 6A).
Presumably, inhibition is mediated by an intramolecular mechanism and
could involve steric hindrance of the SH2C domain or modification of
its binding site.
Identification of a Minimal GAP Binding Region between DokR
Residues 263 and 309--
Since binding of DokR to GAP is predicted to
be phosphorylation-dependent, we devised a binding assay to
map the region of DokR that mediates this interaction. GST fusion
proteins containing full-length or truncated forms of DokR (shown
schematically in Fig. 7A) were
expressed in bacteria and purified. Individual GST-DokR fusion proteins
were then incubated with immunoprecipitates of Lyn in the presence of
ATP in order to generate tyrosine-phosphorylated GST-DokR fusion
proteins. The modified GST fusion proteins were immobilized on
glutathione-Sepharose and tested for their ability to bind to
endogenous GAP in whole cell lysates of untransfected 293T cells by
immunoblotting with GAP antibodies. The relative levels of the GST
fusion proteins and their phosphorylation state were also determined by
immunoblotting with GST and phosphotyrosine antibodies. As shown in
Fig. 7B (center panel), GST fusion proteins containing full-length DokR, residues 136-309, 260-412, and 260-341 were tyrosine-phosphorylated by Lyn (center panel) and
capable of binding to GAP (upper panel). By contrast, GST
alone, unphosphorylated full-length GST-DokR, and a
tyrosine-phosphorylated GST fusion protein containing DokR amino
acids 136-262 failed to bind to GAP. These data define a region of
DokR between residues 1 and 131 that lacks tyrosine phosphorylation
sites, a region of DokR between amino residues 136 and 262 that
contains at least one phosphorylation site that fails to bind GAP, and
a minimal phosphotyrosine-dependent GAP-binding region
between residues 263 and 309.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 7.
A GAP binding region resides between DokR
amino acids 263 and 309. A, schematic showing GST
fusion proteins containing full-length and truncated forms of DokR. The
relative position of the PH and PTB domains and its 13 tyrosine
residues (Y) are shown. Numbers indicate the DokR
residues contained within the GST fusion proteins. B,
equivalent amounts (200 ng) of the GST-DokR fusion proteins shown in
A were pretreated with Lyn and ATP and then adsorbed to
glutathione-Sepharose. Lyn kinase-treated GST fusion proteins
comprising truncated or full-length DokR (FL) or Lyn
kinase-untreated GST-DokR full-length fusion proteins were incubated
with extracts of 293T cells. Precipitates were resolved by SDS-PAGE and
analyzed by immunoblotting with the following antibodies: anti-GAP
(upper panel), anti-Tyr(P) (anti-pY) (center
panel), and anti-GST (lower panel). WB,
Western blot.
|
|
Independent SH2-binding Sites Mediate Association of DokR with GAP
and Nck--
The region of DokR between residues 263 and 309 contains
two tyrosines as follows: Tyr-276 and Tyr-304, which are located within
YXXPXD sequence motifs. This motif is conserved
in the GAP-binding sites of p190RhoGAP (49) and
platelet-derived growth factor receptor (50), suggesting that both
sites in DokR might be involved in GAP recognition. The contribution of
these residues and a third tyrosine, contained within a
YXXPXG motif (Tyr-351), to binding GAP, was
examined by generating FLAG-DokR mutants containing phenylalanine
substitutions of Tyr-276 and/or Tyr-304 and/or Tyr-351. Wild type and
mutant forms of FLAG-DokR (Fig.
8A) were co-expressed with Lyn
in 293T cells. Cell lysates were analyzed by immunoprecipitation with a
FLAG antibody followed by immunoblotting with GAP, DokR, and phosphotyrosine antibodies. As shown in Fig. 8B, all three
DokR single point mutants (Y276F, Y304F, and Y351F) and two of the double point mutants (Y276F/Y351F and Y304F/Y351F) associated with GAP,
albeit less efficiently than with FLAG-DokR WT. However, GAP did not
co-immunoprecipitate with mutants where both Tyr-276 and Tyr-304 were
substituted for phenylalanine (Y276F/Y304F and Y276F/Y304F/Y351F). The
relatively low level of the Y276F/Y304F mutant that was
immunoprecipitated by the FLAG antibody does not account for the lack
of detectable GAP, since GAP was readily detected in complex with
similar levels of other mutants (e.g. Y304F and
Y276F/Y351F). These results suggest that Tyr-276 and Tyr-304 represent
separate GAP-docking sites, which presumably interact with the two GAP
SH2 domains (see Fig. 6A).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 8.
DokR contains dual GAP-docking sites and a
single Nck-binding site. A, illustration showing wild
type (WT) and mutant forms of FLAG-DokR generated by single, double, or
triple phenylalanine (F) substitutions of tyrosines Tyr-276,
Tyr-304, and Tyr-351. B, 293T cells were transfected with
cDNAs encoding Lyn WT alone, FLAG-DokR WT alone, or Lyn
WT plus FLAG-DokR WT, or the FLAG-DokR mutants shown schematically in
A. Anti-FLAG immunoprecipitates (IP) of cellular
extracts (400 µg of protein) were analyzed by SDS-PAGE and
immunoblotted with anti-GAP (upper panel), anti-DokR.3
(center panel), or anti-Tyr(P) (anti-pY) (lower
panel). B, 293T cells were co-transfected with plasmids
encoding Lyn WT and the indicated FLAG-DokR mutants or FLAG-DokR WT.
Cell extracts (400 µg of protein) were immunoprecipitated using
anti-FLAG antibodies, resolved by SDS-PAGE, and transferred to
nitrocellulose. The filter was probed with anti-Nck (upper
panel), anti-GAP (center panel), or anti-DokR.3
antibodies (lower panel). WB, Western blot.
|
|
Recently, Nck, an adaptor protein with three SH3 domains and an SH2
domain, was shown to associate with DokR in a
phosphorylation-dependent manner (33). A synthetic peptide
based on the sequence surrounding Tyr-351 was capable of binding to Nck
only when phosphorylated, suggesting that this residue mediates this
interaction (33). To test this prediction, Lyn was co-expressed with
the wild type and mutant forms of FLAG-DokR shown in Fig.
8A, in 293T cells. Cell lysates were analyzed by
immunoprecipitation with a FLAG antibody followed by immunoblotting
with Nck or GAP antibodies. Consistent with the earlier prediction
(33), all FLAG-DokR mutants in which Tyr-351 was substituted for
phenylalanine failed to associate with Nck while retaining their
capacity to interact with GAP (Fig. 8C). Conversely, the
FLAG-DokR mutant, Y276F/Y304F, which did not associate with GAP, was
capable of interacting with Nck. These results define a specific
Nck-binding site within DokR that includes Tyr-351, which is distinct
from the GAP-specific binding site containing Tyr-276 and Tyr-304.
 |
DISCUSSION |
We have identified DokR as a possible substrate of Lyn and other
Src family kinases. This protein was also recently identified by others
(31) as a substrate of Bcr-Abl tyrosine kinase and a protein that is
capable of interacting in the yeast two-hybrid system with the
intracellular domains of the IL-4 receptor
-chain (32) and the
Tek/Tie2 receptor tyrosine kinase (33). A survey of a range of adult
mouse tissues revealed that DokR protein is expressed primarily in
lymhoid tissues including thymus, lymph node, and spleen (Fig. 2). In
reconstitution experiments using transiently transfected cells,
epitope-tagged DokR was phosphorylated on tyrosine residues when
co-expressed with the Src family kinases, Lyn, Hck, or Src (Fig. 3),
the Bcr-Abl tyrosine kinase (31) or an activated form of Tek/Tie2 (33).
Moreover, stimulation of cell lines that stably expressed DokR with
growth factors or cytokines, including EGF (Fig. 4), insulin,
interleukin-2 (IL-2), IL-3 or IL-4, also resulted in rapid
phosphorylation of DokR (32). Once phosphorylated, DokR was capable of
interacting via specific binding sites with the SH2 domains of GAP
(Figs. 6-8) (31-33) and with the adaptor protein, Nck (Fig. 8) (33).
We have also presented evidence for an interaction between DokR and an
unidentified 150-kDa phosphoprotein (Fig. 5). Together, these results
provide evidence that DokR may participate in a variety of signal
transduction pathways by coordinating the formation of one or more
specific signaling complexes.
Structural similarities suggest that DokR and Dok are distant relatives
of a family of docking proteins that includes the IRS family of
proteins (Fig. 1). These proteins each contain an amino-terminal PH
domain and adjacent PTB domain and multiple phosphorylation sites that
bind to specific SH2-containing proteins. PH domains are thought to
have a role in regulating membrane association. The IRS-1 PH domain is
required for efficient phosphorylation by the insulin receptor,
suggesting that it promotes interaction of IRS-1 with the activated
receptor (51). The PH domains of phospholipase C-
, Bruton's
tyrosine kinase, dynamin, and the serine/threonine kinase, Akt, bind to
the head groups of specific phosphoinositides, which are localized
in cell membranes in vivo, and are thought to promote
membrane targeting of these proteins (52-54). The DokR PTB domain was
shown to mediate binding of DokR to the cytoplasmic domain of an
activated form of the Tek/Tie2 receptor (33) and was proposed to
mediate an interaction with a tyrosine-phosphorylated
NPXY-containing motif in the IL-4 receptor
-chain (32).
Conversely, mutation of the NPXY motif abrogated IL-4-dependent tyrosine phosphorylation of DokR. A model
has been proposed in which DokR is recruited, via its PTB domain, to
phosphorylated target sites within the cytoplasmic domains of specific
receptors (32). DokR is then phosphorylated, either by the intrinsic
tyrosine kinase activity of the receptor or by a cytoplasmic tyrosine
kinase associated with the receptor, thereby promoting subsequent
interactions between DokR and specific SH2-containing proteins (32,
33).
Distinct phosphorylation-dependent binding sites for GAP
and Nck were identified in DokR (Figs. 7 and 8). Since mutation of two
potential phosphorylation sites, Tyr-276 and Tyr-304, but neither site
alone abolished the interaction between DokR and GAP, it seems likely
that both sites mediate binding to GAP in vivo. By contrast,
substitution of Tyr-351 alone ablated the interaction between Nck and
DokR. The simplest explanation for these observations is that
interaction of GAP with DokR is mediated by the two GAP SH2 domains and
the DokR phosphorylation sites, Tyr-276 and Tyr-304, whereas binding of
DokR to Nck is mediated by the single SH2 domain of Nck and the
phosphorylation site at Tyr-351. In support of the notion that two
binding sites facilitate GAP binding, GST fusion proteins containing
either of the GAP SH2 domains were capable of binding to DokR (Fig. 6).
In an earlier study the GAP SH2C domain failed to bind to DokR (32).
However, the GST-SH2C fusion protein used in this experiment was not
shown to be competent to bind to another GAP-interacting protein
(e.g. p190RhoGAP) (48, 49), raising the possibility
that it was not functional. Previous studies indicate that association
of GAP with p190RhoGAP is mediated by both of its SH2 domains
(48, 49). Interestingly, the GAP SH2 domains appear to bind
cooperatively to p190RhoGAP since a GST fusion protein
containing the two SH2 domains and SH3 domain of GAP bound to
p190RhoGAP with higher efficiency than the individual SH2
domains. We found no evidence of cooperative or synergistic binding of
DokR by a GST fusion protein containing both SH2 domains compared with
the isolated SH2 domains (Fig. 7). This implies that the molecular basis of the interaction between GAP and p190RhoGAP and that
between GAP and DokR is fundamentally different. This difference may be
related to the number of residues that separate the tandem
phosphorylation sites in the two proteins; in p190RhoGAP the
predicted GAP SH2-binding sites are separated by 17 residues and in
DokR by 27 residues (49).
Simultaneous engagement of two SH2 domains within a protein may have a
role in regulating catalytic activity or protein-protein interactions.
The enzymatic activity of SHP-2, a phosphotyrosine phosphatase with
tandem SH2 domains, is regulated by interactions with the
phosphopeptide ligands that bind to its SH2 domains. Mono-phosphorylated peptides that interact with a single SH2 domain produce a 10-fold activation, whereas bi-phosphorylated peptides that
engage both SH2 domains activate SHP-2 approximately 100-fold (55).
Structural studies have shown that binding of a phosphopeptide to the
carboxyl-terminal SH2 domain alters the structure of SHP-2, disrupting
an inhibitory intramolecular interaction with the catalytic domain
(56). Similarly, interaction of the tandem phosphorylation sites of
p190RhoGAP with the GAP SH2 domains alters the conformation of
GAP within its SH3 domain (49). This modification enhances SH3 binding capacity and appears to promote interactions between GAP and specific target proteins. Whether interaction of DokR is capable of inducing a
similar conformational change in the GAP SH3 domain or regulates GAP
enzymatic activity needs to be tested using purified recombinant proteins. It is interesting to note that a GAP deletion mutant lacking
the SH2 and SH3 domains has reduced catalytic activity compared with
wild type GAP, suggesting that this region may indeed have a role in
GAP regulation (57).
Since amino acid substitution of Tyr-276, Tyr-304, and Tyr-351 in
combination did not abolish tyrosine phosphorylation of DokR, it is
possible that DokR contains additional binding sites for SH2- or
PTB-containing proteins (Fig. 8). The additional phosphorylation site
(or sites) is predicted to reside between amino acids Met-136 and
Gly-262 (Fig. 7), a region that contains 5 tyrosine residues. Further
studies are needed to establish which of these tyrosines represent
phosphorylation sites or SH2/PTB-binding sites. It is interesting to
speculate that p150, the unidentified protein that co-immunoprecipitated with DokR from lysates of EGF-stimulated BaF/3
cells, has an SH2 or PTB domain that mediates its interaction with
DokR. The possibility that phosphorylation of p150 induces it to
associate with the DokR PTB domain or, alternatively, that these
proteins are constitutively associated in unstimulated cells and p150
is only detectable after EGF stimulation because it becomes phosphorylated should also be considered.
What is the physiological relevance of DokR interactions involving GAP,
Nck, and p150? Since GAP is capable of negatively regulating Ras by
enhancing its intrinsic GTPase activity, one attractive model is that
DokR links GAP to attenuation of Ras signaling, perhaps by recruiting
GAP to cell membranes (32). Indeed, overexpression of DokR in 32D cells
was shown to inhibit the activation of mitogen-activated protein
kinases and expression of an AP-1 responsive reporter gene following
stimulation with IL-2 (32), processes that are thought to be
Ras-dependent. Conversely, primary T cells from the
hairless (hr/hr) strain of mice, which were shown to express 3-5-fold
lower levels of DokR than wild type mice, were shown to be
hyper-responsive to stimulation with cytokines and concomitant T cell
receptor activation (32). Although these results are consistent with a
critical role for GAP, the contribution to negative regulation by Nck
and other DokR-interacting proteins, such as p150, also needs to be
investigated. We are now exploring the potential of the mutant forms of
DokR that lacks the ability to interact with GAP, Nck, or both proteins
to function as dominant negative mutants with which we should be able
to address the relevance of these different pathways in DokR signaling.
 |
ACKNOWLEDGEMENTS |
We thank A. Verhagen and A. Burgess for
comments on the manuscript and members of the molecular biology
laboratory for constructive advice and discussions. We also thank
Guo-Fen Tu for performing the DNA sequence analysis, Cathy Quilici for
mouse dissections, and members of the Walter and Eliza Hall Institute
of Medical Research animal facility for assisting in generating rabbit
polyclonal antisera. We gratefully acknowledge those who provided
reagents that were used in this study (see "Experimental
Procedures").
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 61-3-9341 3155;
Fax: 61-3-9341 3191; E-mail Peter.Lock@Ludwig.edu.au.
 |
ABBREVIATIONS |
The abbreviations used are:
SH2 and SH3, Src
homology 2 and 3;
DokR, Dok-related protein;
Dok, p62dok;
GAP, RasGTPase-activating protein;
IRS, insulin receptor substrate;
HS1, hematopoietic lineage cell-specific protein;
LckBP1, Lck-binding
protein 1;
EGF, epidermal growth factor;
EGFR, EGF receptor;
FGF, fibroblast growth factor;
IL, interleukin;
FRS2, FGF receptor substrate
2;
SNT-1 and -2, suc1-associated neurotrophic factor target-1 and -2;
p190RhoGAP, 190 kDa Rho family GTPase activating protein;
SHP-2, SH2-containing protein-tyrosine phosphatase-2;
PH, pleckstrin
homology;
PTB, phosphotyrosine binding;
Tyr(P), phosphotyrosine;
PCR, polymerase chain reaction;
DTT, dithiothreitol;
FCS, fetal calf serum;
GST, glutathione S-transferase;
PAGE, polyacrylamide gel
electrophoresis;
WT, wild type.
 |
REFERENCES |
| 1.
|
Erpel, T.,
and Courtneidge, S. A.
(1995)
Curr. Opin. Cell Biol.
7,
176-182[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Lowell, C. A.,
and Soriano, P.
(1996)
Genes Dev.
10,
1845-1857[Free Full Text]
|
| 3.
|
Schwartzberg, P. L.
(1998)
Oncogene
17,
1463-1468[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Chan, A. C.,
Dalton, M.,
Johnson, R.,
Kong, G. H.,
Wang, T.,
Thoma, R.,
and Kurosaki, T.
(1995)
EMBO J.
14,
2499-2508[Medline]
[Order article via Infotrieve]
|
| 5.
|
Schlaepfer, D. D.,
and Hunter, T.
(1996)
Mol. Cell. Biol.
16,
5623-5633[Abstract]
|
| 6.
|
Rawlings, D. J.,
Scharenberg, A. M.,
Park, H.,
Wahl, M. I.,
Lin, S.,
Kato, R. M.,
Fluckiger, A. C.,
Witte, O. N.,
and Kinet, J. P.
(1996)
Science
271,
822-825[Abstract]
|
| 7.
|
Wu, H.,
Reynolds, A. B.,
Kanner, S. B.,
Vines, R. R.,
and Parsons, J. T.
(1991)
Mol. Cell. Biol.
11,
5113-5124[Abstract/Free Full Text]
|
| 8.
|
Flynn, D. C.,
Leu, T. H.,
Reynolds, A. B.,
and Parsons, J. T.
(1993)
Mol. Cell. Biol.
13,
7892-7900[Abstract/Free Full Text]
|
| 9.
|
Davis, S.,
Lu, M. L.,
Lo, S. H.,
Lin, S.,
Butler, J. A.,
Druker, B. J.,
Roberts, T. M.,
An, Q.,
and Chen, L. B.
(1991)
Science
252,
712-715[Abstract/Free Full Text]
|
| 10.
|
Sakai, R.,
Iwamatsu, A.,
Hirano, N.,
Ogawa, S.,
Tanaka, T.,
Mano, H.,
Yazaki, Y.,
and Hirai, H.
(1994)
EMBO J.
13,
3748-3756[Medline]
[Order article via Infotrieve]
|
| 11.
|
Ishino, M.,
Ohba, T.,
Sasaki, H.,
and Sasaki, T.
(1995)
Oncogene
11,
2331-2338[Medline]
[Order article via Infotrieve]
|
| 12.
|
Alexandropoulos, K.,
and Baltimore, D.
(1996)
Genes Dev.
10,
1341-1355[Abstract/Free Full Text]
|
| 13.
|
Yamanashi, Y.,
Okada, M.,
Semba, T.,
Yamori, T.,
Umemori, H.,
Tsunasawa, S.,
Toyoshima, K.,
Kitamura, D.,
Watanabe, T.,
and Yamamoto, T.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
3631-3635[Abstract/Free Full Text]
|
| 14.
|
Takemoto, Y.,
Furuta, M.,
Li, X. K.,
Strong-Sparks, W. J.,
and Hashimoto, Y.
(1995)
EMBO J.
14,
3403-3414[Medline]
[Order article via Infotrieve]
|
| 15.
|
Feshchenko, E. A.,
Langdon, W. Y.,
and Tsygankov, A. Y.
(1998)
J. Biol. Chem.
273,
8323-8331[Abstract/Free Full Text]
|
| 16.
|
Carpino, N.,
Wisniewski, D.,
Strife, A.,
Marshak, D.,
Kobayashi, R.,
Stillman, B.,
and Clarkson, B.
(1997)
Cell
88,
197-204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Yamanashi, Y.,
and Baltimore, D.
(1997)
Cell
88,
205-211[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Iwashima, M.,
Irving, B. A.,
van Oers, N. S.,
Chan, A. C.,
and Weiss, A.
(1994)
Science
263,
1136-1139[Abstract/Free Full Text]
|
| 19.
|
Chan, V. W.,
Lowell, C. A.,
and DeFranco, A. L.
(1998)
Curr. Biol.
8,
545-553[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Smith, K. G. C.,
Tarlinton, D. M.,
Doody, G. M.,
Hibbs, M. L.,
and Fearon, D. T.
(1998)
J. Exp. Med.
187,
807-811[Abstract/Free Full Text]
|
| 21.
|
Nishizumi, H.,
Horikawa, K.,
Mlinaric-Rascan, I.,
and Yamamoto, T.
(1998)
J. Exp. Med.
187,
1343-1348[Abstract/Free Full Text]
|
| 22.
|
Hibbs, M. L.,
Tarlinton, D. M.,
Armes, J.,
Grail, D.,
Hodgson, G.,
Maglitto, R.,
Stacker, S. A.,
and Dunn, A. R.
(1995)
Cell
83,
301-311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Nishizumi, H.,
Taniuchi, I.,
Yamanashi, Y.,
Kitamura, D.,
Ilic, D.,
Mori, S.,
Watanabe, T.,
and Yamamoto, T.
(1995)
Immunity
3,
549-560[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Chan, V. W.,
Meng, F.,
Soriano, P.,
DeFranco, A. L.,
and Lowell, C. A.
(1997)
Immunity
7,
69-81[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Yamanashi, Y.,
Fukuda, T.,
Nishizumi, H.,
Inazu, T.,
Higashi, K.,
Kitamura, D.,
Ishida, T.,
Yamamura, H.,
Watanabe, T.,
and Yamamoto, T.
(1997)
J. Exp. Med.
185,
1387-1392[Abstract/Free Full Text]
|
| 26.
|
Qin, S.,
Minami, Y.,
Kurosaki, T.,
and Yamamura, H.
(1997)
J. Biol. Chem.
272,
17994-17999[Abstract/Free Full Text]
|
| 27.
|
Tilbrook, P. A.,
Ingley, E.,
Williams, J. H.,
Hibbs, M. L.,
and Klinken, S. P.
(1997)
EMBO J.
16,
1610-1619[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Meng, F.,
and Lowell, C. A.
(1998)
EMBO J.
17,
4391-4403[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Suzuki, T.,
Shoji, S.,
Yamamoto, K.,
Nada, S.,
Okada, M.,
Yamamoto, T.,
and Honda, Z.
(1998)
J. Immunol.
161,
3694-3701[Abstract/Free Full Text]
|
| 30.
|
Lock, P.,
Abram, C. L.,
Gibson, T.,
and Courtneidge, S. A.
(1998)
EMBO J.
17,
4346-4357[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Di Cristofano, A.,
Carpino, N.,
Dunant, N.,
Friedland, G.,
Kobayashi, R.,
Strife, A.,
Wisniewski, D.,
Clarkson, B.,
Pandolfi, P. P.,
and Resh, M. D.
(1998)
J. Biol. Chem.
273,
4827-4830[Abstract/Free Full Text]
|
| 32.
|
Nelms, K.,
Snow, A. L.,
Hu-Li, J.,
and Paul, W. E.
(1998)
Immunity
9,
13-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Jones, N.,
and Dumont, D. J.
(1998)
Oncogene
17,
1097-1108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Sotirellis, N.,
Johnson, T. M.,
Hibbs, M. L.,
Stanley, I. J.,
Stanley, E.,
Dunn, A. R.,
and Cheng, H. C.
(1995)
J. Biol. Chem.
270,
29773-29780[Abstract/Free Full Text]
|
| 35.
|
Altschul, S. F.,
Madden, T. L.,
Schaffer, A. A.,
Zhang, J.,
Zhang, Z.,
Miller, W.,
and Lipman, D. J.
(1997)
Nucleic Acids Res.
25,
3389-3402[Abstract/Free Full Text]
|
| 36.
|
Marengere, L. E.,
and Pawson, T.
(1992)
J. Biol. Chem.
267,
22779-22786[Abstract/Free Full Text]
|
| 37.
|
Walker, F.,
Hibbs, M. L |